EP3927352A4 - Récepteurs antigéniques chimériques d'immunosurveillance artificielle (ai-car) et cellules les exprimant - Google Patents

Récepteurs antigéniques chimériques d'immunosurveillance artificielle (ai-car) et cellules les exprimant Download PDF

Info

Publication number
EP3927352A4
EP3927352A4 EP20758532.4A EP20758532A EP3927352A4 EP 3927352 A4 EP3927352 A4 EP 3927352A4 EP 20758532 A EP20758532 A EP 20758532A EP 3927352 A4 EP3927352 A4 EP 3927352A4
Authority
EP
European Patent Office
Prior art keywords
immunosurveillance
artificial
car
same
cells expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20758532.4A
Other languages
German (de)
English (en)
Other versions
EP3927352A2 (fr
Inventor
Donald E. Staunton
John M. LUK
John M. Harlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbele Ltd
Original Assignee
Arbele Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbele Ltd filed Critical Arbele Ltd
Publication of EP3927352A2 publication Critical patent/EP3927352A2/fr
Publication of EP3927352A4 publication Critical patent/EP3927352A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP20758532.4A 2019-02-21 2020-02-21 Récepteurs antigéniques chimériques d'immunosurveillance artificielle (ai-car) et cellules les exprimant Pending EP3927352A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962808823P 2019-02-21 2019-02-21
US201962808815P 2019-02-21 2019-02-21
US201962808833P 2019-02-21 2019-02-21
PCT/US2020/019376 WO2020172643A2 (fr) 2019-02-21 2020-02-21 Récepteurs antigéniques chimériques d'immunosurveillance artificielle (ai-car) et cellules les exprimant

Publications (2)

Publication Number Publication Date
EP3927352A2 EP3927352A2 (fr) 2021-12-29
EP3927352A4 true EP3927352A4 (fr) 2023-06-14

Family

ID=72144733

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20758532.4A Pending EP3927352A4 (fr) 2019-02-21 2020-02-21 Récepteurs antigéniques chimériques d'immunosurveillance artificielle (ai-car) et cellules les exprimant

Country Status (7)

Country Link
US (1) US20220185882A1 (fr)
EP (1) EP3927352A4 (fr)
JP (1) JP2022521278A (fr)
KR (1) KR20210132668A (fr)
CN (1) CN113891718A (fr)
AU (1) AU2020224160A1 (fr)
WO (1) WO2020172643A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240269281A1 (en) * 2021-06-23 2024-08-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Car-t cell therapy for triple negative breast cancer
AU2022303363A1 (en) * 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CN113402620B (zh) * 2021-07-30 2021-12-10 中山大学 细胞因子联合嵌合抗原受体的融合蛋白及其应用
WO2023232746A1 (fr) * 2022-05-30 2023-12-07 Mediterranea Theranostic S.R.L. Constructions de récepteurs antigéniques chimériques anti-trop-2 activé destinées à être utilisées dans une thérapie anticancéreuse

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130598A1 (fr) * 2015-02-09 2016-08-18 University Of Florida Research Foundation, Inc. Récepteur antigénique chimérique bispécifique et ses utilisations
WO2017075537A1 (fr) * 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions et méthodes pour le du traitement du cancer
WO2020172641A1 (fr) * 2019-02-21 2020-08-27 Arbele Limited Récepteur antigénique chimérique d'immunosurveillance artificielle et cellules l'exprimant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
KR20170032406A (ko) * 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
US10738116B2 (en) * 2015-03-19 2020-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
MA44314A (fr) * 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
CA3034873A1 (fr) * 2016-08-26 2018-03-01 Baylor College Of Medicine Recepteurs de cytokine constitutivement actifs de therapie cellulaire
AU2018227583B2 (en) * 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130598A1 (fr) * 2015-02-09 2016-08-18 University Of Florida Research Foundation, Inc. Récepteur antigénique chimérique bispécifique et ses utilisations
WO2017075537A1 (fr) * 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions et méthodes pour le du traitement du cancer
WO2020172641A1 (fr) * 2019-02-21 2020-08-27 Arbele Limited Récepteur antigénique chimérique d'immunosurveillance artificielle et cellules l'exprimant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAIYING QIN ET AL: "Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22", MOLECULAR THERAPY - ONCOLYTICS, vol. 11, 1 December 2018 (2018-12-01), pages 127 - 137, XP055770751, ISSN: 2372-7705, DOI: 10.1016/j.omto.2018.10.006 *
MORRIS RHIANNON ET AL: "The molecular details of cytokine signaling via the JAK/STAT pathway : Cytokine Signaling via the JAK/STAT Pathway", PROTEIN SCIENCE, vol. 27, no. 12, 1 December 2018 (2018-12-01), US, pages 1984 - 2009, XP055809868, ISSN: 0961-8368, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237706/pdf/PRO-27-1984.pdf> DOI: 10.1002/pro.3519 *
SUBRAMANIAM S.VAIDYANATHAN ET AL: "Evidence for the Involvement of JAK/STAT Pathway in the Signaling Mechanism of Interleukin-17", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 19 August 1999 (1999-08-19), United States, pages 14 - 19, XP093019453, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0006291X99911567/pdf?md5=08681cdcb790ebd1a367b746a57406c6&pid=1-s2.0-S0006291X99911567-main.pdf> [retrieved on 20230131], DOI: 10.1006/bbrc.1999.1156 *

Also Published As

Publication number Publication date
US20220185882A1 (en) 2022-06-16
WO2020172643A2 (fr) 2020-08-27
WO2020172643A3 (fr) 2020-11-12
JP2022521278A (ja) 2022-04-06
EP3927352A2 (fr) 2021-12-29
KR20210132668A (ko) 2021-11-04
AU2020224160A1 (en) 2021-08-26
CN113891718A (zh) 2022-01-04

Similar Documents

Publication Publication Date Title
IL284744A (en) GPRC5D chimeric antigen receptors and cells expressing them
EP3927352A4 (fr) Récepteurs antigéniques chimériques d&#39;immunosurveillance artificielle (ai-car) et cellules les exprimant
EP3837279A4 (fr) Constructions de récepteurs de cellules t et leurs utilisations
EP3743513A4 (fr) Cellules nk-92 modifiées par un récepteur antigénique chimérique
EP3567049A4 (fr) Récepteur antigénique chimérique et cellules tueuses naturelles exprimant celui-ci
EP3916019A4 (fr) Récepteur antigénique chimérique spécifique de la mésothéline et lymphocytes t l&#39;exprimant
EP3749338A4 (fr) Anticorps bcma humanisé et cellules bcma-car-t
EP3630980A4 (fr) Préparation cellulaire de récepteurs antigéniques chimériques et utilisations de celle-ci
EP3820484A4 (fr) Récepteurs antigéniques chimériques specifiques de ror-1 et utilisations associées
EP3824096A4 (fr) Nouveaux anticorps et leurs procédés de préparation et d&#39;utilisation
EP4003373A4 (fr) Cellules exprimant des récepteurs d&#39;antigènes chimériques et des récepteurs de stimulation chimériques et utilisations associées
EP3919515A4 (fr) Récepteur d&#39;antigène chimère et utilisation correspondante
EP4045539A4 (fr) Récepteur antigénique chimérique amélioré pour l&#39;ingénierie de cellules effectrices immunitaires et son utilisation
EP3812401A4 (fr) Récepteur antigénique chimérique comprenant un troisième récepteur de signal et utilisation associée
EP4041759A4 (fr) Récepteur antigénique chimérique amélioré pour ingénierie cellulaire effectrice immunitaire et son utilisation
EP3827025A4 (fr) Récepteur antigénique chimérique à base de gd2 et utilisation associée
EP3757133A4 (fr) Récepteur antigénique chimérique isolé, lymphocyte t modifié le comprenant et utilisation associée
EP3919517A4 (fr) Protéine de fusion tcr et cellule exprimant une protéine de fusion tcr
EP3802615A4 (fr) Récepteurs antigéniques chimériquesspecifiques de muc16 et utilisations associées
EP4023678A4 (fr) Récepteur d&#39;antigène chimérique et cellule effectrice immunitaire exprimant un récepteur d&#39;antigène chimérique
EP3737688A4 (fr) Cellules immunitaires exprimant un récepteur antigénique chimérique
EP3765070A4 (fr) Cellules spécifiquement modifiées, anticorps de modulation immunitaire de lymphocytes t et leurs procédés d&#39;utilisation
EP3962956A4 (fr) Anticorps anti-hvem et leur utilisation
EP4013798A4 (fr) Récepteurs antigéniques chimériques et leurs utilisations
EP3999550A4 (fr) Récepteurs antigéniques chimériques anti-dll3 et leurs utilisations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210917

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063477

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20230208BHEP

Ipc: A61P 35/00 20060101ALI20230208BHEP

Ipc: A61K 35/17 20150101AFI20230208BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20230516

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20230510BHEP

Ipc: A61P 35/00 20060101ALI20230510BHEP

Ipc: A61K 35/17 20150101AFI20230510BHEP